•  
  •  
 

International Journal of Health and Allied Sciences

Abstract

Polmacoxib, a novel nonsteroidal anti-inflammatory drug (NSAID), has shown a promised therapeutic option for the management of osteoarthritis and other inflammatory conditions. This drug review mainly aims to provide a comprehensive overview of polmacoxib, focusing on its pharmacological properties, clinical efficacy, safety profile, and potential therapeutic applications. Polmacoxib is a notable drug due to its dual mechanism of action, combining selective COX-2 inhibition with inhibition of carbonic anhydrase, which may contribute to its enhanced anti-inflammatory and analgesic effects. Being a selective COX-2 inhibitor, it helps minimize gastrointestinal side effects typically caused by conventional nonselective NSAIDs. Data from clinical studies suggest that polmacoxib provides statistically and clinically significant analgesic and remarkable benefits. Clinical trials have demonstrated that polmacoxib provides substantial pain relief and functional improvement in patients with osteoarthritis.This review also explores the molecular basis of polmacoxib’s action, its pharmacokinetics, and emerging evidence from post-marketing surveillance.

Download

Share

COinS